840 reports of this reaction
1.5% of all DASATINIB reports
#16 most reported adverse reaction
MALIGNANT NEOPLASM PROGRESSION is the #16 most commonly reported adverse reaction for DASATINIB, manufactured by E.R. Squibb & Sons, L.L.C.. There are 840 FDA adverse event reports linking DASATINIB to MALIGNANT NEOPLASM PROGRESSION. This represents approximately 1.5% of all 55,495 adverse event reports for this drug.
Patients taking DASATINIB who experience malignant neoplasm progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MALIGNANT NEOPLASM PROGRESSION is a less commonly reported adverse event for DASATINIB, but still significant enough to appear in the safety profile.
In addition to malignant neoplasm progression, the following adverse reactions have been reported for DASATINIB:
The following drugs have also been linked to malignant neoplasm progression in FDA adverse event reports:
MALIGNANT NEOPLASM PROGRESSION has been reported as an adverse event in 840 FDA reports for DASATINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
MALIGNANT NEOPLASM PROGRESSION accounts for approximately 1.5% of all adverse event reports for DASATINIB, making it a notable side effect.
If you experience malignant neoplasm progression while taking DASATINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.